Durand P G, Lehot J J, Foëx P
Department of Anaesthesia and Intensive Care, Hôpital Cardio-vasculaire et Pneumologique, Lyon, France.
Can J Anaesth. 1991 Jan;38(1):75-89. doi: 10.1007/BF03009168.
Verapamil was the first calcium-channel blocker (CCB). It has been used since 1962 in Europe then in Japan for its antiarrhythmic and coronary vasodilator effects. The CCB have become prominent cardiovascular drugs during the last 15 years. Many experimental and clinical studies have defined their mechanism of action, the effects of new drugs in this therapeutic class, and their indications and interactions with other drugs. Due to the large number of patients treated with CCB it is important for the anaesthetist to know the general and specific problems involved during the perioperative period, the interactions with anaesthetics and the practical use of these drugs.
维拉帕米是第一种钙通道阻滞剂(CCB)。自1962年起,它就在欧洲使用,随后在日本因其抗心律失常和冠状动脉扩张作用而被使用。在过去15年中,CCB已成为重要的心血管药物。许多实验和临床研究已经明确了它们的作用机制、该治疗类别中新药的效果、它们的适应证以及与其他药物的相互作用。由于接受CCB治疗的患者数量众多,麻醉医生了解围手术期涉及的一般和特殊问题、与麻醉药的相互作用以及这些药物的实际应用非常重要。